Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

DNI Metals | Status on Trading, Fraud Trial, and Permits

DNI Metals (CSE: DNI | OTC: DMNKF) Dan Wei r of DNI Metals sits down with Maurice Jackson of Proven and Probable to provide shareholders updates on when trading will commence on the Canadian Stock Exchange, judicial ma...
Maurice Jackson | April 1, 2020 |

FDA Approval of Peanut Allergy Treatment Expected Next Year

The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. In a Nov. 7 research note, ROTH Capital Partners analyst Zegbeh Jallah reported that with respect to Aimmune Therapeutics Inc. (AIMT:NASDAQ) , "all eyes r...
Streetwise Reports | November 14, 2019 |

Memphasys, Moderna, Paion - Investments in solutions with potential

Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive thi...
Mario Hose | June 2, 2020 |

Analyst: G1 Minimizes the Carnage of Chemotherapy

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy ...
Streetwise Reports | July 2, 2020 |

Could DehydraTECH CBD be Worth $3 Billion a Year to Lexaria?

PCG Digital -- Hypertension, or high blood pressure as it's commonly known, affects over three million Americans every year and is a primary or contributing cause of death for 25% of them. On a global scale, hypertension kills roughly 7.6 milli on people per year . L...
Featured Submission | March 9, 2021 |

U.S. spot Bitcoin ETFs are live – what happens to Canada’s crypto ETFs?

By Shaed Hashimkhial The SEC’s endorsement of U.S. spot Bitcoin ETFs significantly influenced the cryptocurrency markets. Shortly after the announcement, we witnessed a substantial rally in Bitcoin, a notable increase in Ethereum’s...
Research | March 26, 2024 |

Why Provention Bio Is in My Portfolio

Quite often when I write about companies I'm just about the only one doing so. It's in these situations that Tailwinds can add value by not only highlighting our investment thesis, but in educating investors about a company for which there is little to no publicly avail...
Streetwise Reports | August 26, 2019 |

Avedro Shares Looking Up 35% with Glaukos Merger

Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. After the markets closed yesterday afternoon, corneal modeling platform firm Avedro Inc...
Streetwise Reports | August 13, 2019 |

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis

The details of this study and a second one are outlined in a ROTH Capital Partners report. In an Oct. 16 research note, ROTH Capital Partners analyst Jerry Isaacson reported that Matinas BioPharma Holdings Inc. (MTNB:NYSE.American) launched its first clinical trial ...
Streetwise Reports | October 23, 2019 |
1 2 3 4 5 6 7 8 9 10 ...